Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.06 +1.23%

+$0.04 today

Market cap
$227.58M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 4.13M

Average 3.33M

CABA Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Cabaletta Bio, Inc.NASDAQ: CABA

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $337K fell 30.5% year over year, behind the -16.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -30.5% toward the trailing-twelve-month pace of -16.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$337K-3.2% QoQ
Last fiscal yearDec 2025
$1.65M-3.8% YoY
LTMMar 2026
$1.5M-16.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.5%——
1 year-3.8%——
3-year CAGR+11.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
1.65M USD
Year-over-year change
-3.8%
4-year CAGR
+22.4%

Depreciation & Amortization vs competitors

How CABA compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -16.9% is the 8th highest of 11, against a peer median of -1.3%.
  • Over three fiscal years its annual growth of +11.8% compares with a peer median of -1.9%.
CABA Competitors
Depreciation & Amortization for CABA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1.25B USD+83349.3%+52.5%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$12.13M USD-8.0%-4.7%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$10.43M USD-42.2%-11.2%33645.2%
HUMAHumacyte, Inc.LTM Mar 2026$6.86M USD+34.4%-13.4%340.1%
EDITEditas Medicine, Inc.LTM Mar 2026$4.17M USD-34.0%-5.9%10.8%
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.72M EUR-0.9%+1.0%20.3%
IMMPImmutep LimitedFY2025A$2.39M AUD+5.6%+5.0%47.4%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$1.99M USD-1.7%-30.8%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$1.65M USD-23.4%+19.6%—
CABACabaletta Bio, Inc.LTM Mar 2026$1.5M USD-16.9%+11.8%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$416K USD+0.0%+17.0%—
Peer median (excluding CABA) —-1.3%-1.9%47.4%

Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Depreciation & Amortization733K1.18M1.43M1.71M1.65M
Deferred Income Tax00000
Stock-Based Compensation5.8M6.9M11.34M19.47M20.94M
Change in Working Capital5.58M(4.3M)101K1.61M(379K)
Accounts Receivables00000
Inventory00000
Accounts Payables975K(28K)1.68M1.01M1.55M
Other Working Capital4.61M(4.27M)(1.57M)600K(1.93M)
Other Non-Cash Items62K2.82M1.26M4.86M14.57M
Operating Cash Flow(34.11M)(46.38M)(53.55M)(88.22M)(131.08M)
Capital Expenditures(1.17M)(2.45M)(687K)(2.21M)(1.23M)
Acquisitions (Net)024.76K000
Purchases of Investments0(49.76M)(84.26M)0(99.04M)
Sales of Investments7.17M25M62.5M49.5M50M
Other Investing Activities0(24.76K)000
Investing Cash Flow6M(27.22M)(22.45M)47.29M(50.27M)
Debt Repayment000(897K)(6.26M)
Common Stock Issued48.25M32.86M185.2M10.88M106.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities650K127K2.43M1.7M0
Financing Cash Flow48.9M32.98M187.63M11.68M100.35M
Effect of Forex Changes000(20K)19K
Net Change in Cash20.79M(40.62M)111.63M(29.28M)(80.98M)
Free Cash Flow(35.28M)(48.83M)(54.24M)(90.43M)(132.31M)

Cabaletta Bio, Inc.

NASDAQ:CABA

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.